SABS on XNAS, Health Care, SAB Biotherapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Institutional holders rose 18% to 100 while losses reached $80.5M over 12 months.
BadShort interest rose 4.7% over two weeks, now 5.6% of shares
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Industry
Biological products, (no diagnostic substances) (Health Care)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $22.3M.
31 Dec 2021RevenueNet incomeNet losstallest bar $45.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$22.3M
30 Jun 2026
–
-$22.5M
31 Mar 2026
–
-$18.9M
31 Dec 2025
–
-$16.9M
30 Sep 2025
–
$45.4M
30 Jun 2025
–
-$10.1M
31 Mar 2025
–
-$5.2M
31 Dec 2024
$115K
-$11.4M
30 Sep 2024
–
-$10.3M
30 Jun 2024
$263K
-$7.3M
31 Mar 2024
$945K
-$5.0M
31 Dec 2023
$305K
-$22.9M
30 Sep 2023
$1.3M
-$5.1M
30 Jun 2023
$86K
-$6.9M
31 Mar 2023
$581K
-$7.4M
31 Dec 2022
$2.2M
-$7.9M
30 Sep 2022
$3.6M
-$7.1M
30 Jun 2022
$6.4M
-$4.8M
31 Mar 2022
$11.8M
$986K
31 Dec 2021
$11.1M
-$17.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$80.5M
$18.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-42.8%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$104.0M
$110.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.34
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.2
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+18%
100 13F filers vs 85
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
87%
78.3M shares held by 13F filers (30 Sep 2026) of 90.1M outstanding (2 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
5.6%
5.0M shares sold short (30 Oct 2026) of 90.1M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.3
5.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+4.7%
4.8M shares sold short in the report before, 5.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
8
8 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.0×
8 articles in the last 7 days; its usual week has 1.
Price $2.81 on 20 Nov 2026, -26% over 12 months (12-month range $2.49 to $4.59)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).Revenue per quarter. Revenue $115K in the latest quarter, -62% on a year earlier.Capital spending per quarter. Capital spending $1.3M in the latest quarter.Institutional holders (13F filers). 100 13F filers reported holding it in the latest 13F quarter, +194% on a year earlier.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Mar 2021: $16.9M; public on 13 May 2022
Quarter ended 30 Jun 2021: $18.2M; public on 11 Aug 2022
Quarter ended 30 Sep 2021: $14.7M; public on 15 Nov 2022
Quarter ended 31 Dec 2021: $11.1M; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $11.8M, -30% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $6.4M, -65% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $3.6M, -76% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $2.2M, -80% on a year earlier; public on 15 Apr 2023
Quarter ended 31 Mar 2023: $581K, -95% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $86K, -99% on a year earlier; public on 22 Aug 2023
Quarter ended 30 Sep 2023: $1.3M, -65% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $305K, -86% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $945K, +63% on a year earlier; public on 21 May 2024
Quarter ended 30 Jun 2024: $263K, +208% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Dec 2024: $115K, -62% on a year earlier; public on 1 Apr 2025
Capital spending per quarter
Quarter ended 31 Mar 2021: $1.9M; public on 13 May 2022
Quarter ended 30 Jun 2021: $3.5M; public on 11 Aug 2022
Quarter ended 30 Sep 2021: $3.2M; public on 15 Nov 2022
Quarter ended 31 Dec 2021: $2.4M; public on 30 Mar 2022
Quarter ended 31 Mar 2022: $1.4M, -28% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $613K, -82% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $79K, -98% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $118K, -95% on a year earlier; public on 15 Apr 2023
Quarter ended 31 Mar 2023: $21K, -98% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $23K, -96% on a year earlier; public on 22 Aug 2023
Quarter ended 30 Sep 2023: $85K, +8.7% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $68K, -42% on a year earlier; public on 30 Mar 2024
Quarter ended 31 Mar 2024: $129K, +506% on a year earlier; public on 21 May 2024
Quarter ended 30 Jun 2024: $53K, +131% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $100K, +18% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $55K, -18% on a year earlier; public on 1 Apr 2025
Quarter ended 31 Mar 2026: $983K; public on 13 May 2026
Quarter ended 30 Jun 2026: $1.6M; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.3M; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 32; public on 14 Feb 2022
31 Mar 2022 report: 27; public on 16 May 2022
30 Jun 2022 report: 37; public on 15 Aug 2022
30 Sep 2022 report: 37; public on 14 Nov 2022
31 Dec 2022 report: 36; public on 14 Feb 2023
31 Mar 2023 report: 38; public on 15 May 2023
30 Jun 2023 report: 35; public on 14 Aug 2023
30 Sep 2023 report: 32; public on 14 Nov 2023
31 Dec 2023 report: 42; public on 14 Feb 2024
31 Mar 2024 report: 23; public on 15 May 2024
30 Jun 2024 report: 22; public on 14 Aug 2024
30 Sep 2024 report: 23; public on 14 Nov 2024
31 Dec 2024 report: 25; public on 14 Feb 2025
31 Mar 2025 report: 26; public on 15 May 2025
30 Jun 2025 report: 22; public on 14 Aug 2025
30 Sep 2025 report: 34; public on 14 Nov 2025
31 Dec 2025 report: 48; public on 17 Feb 2026
31 Mar 2026 report: 75; public on 15 May 2026
30 Jun 2026 report: 85; public on 14 Aug 2026
30 Sep 2026 report: 100; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 100 (30 Sep 2026), 3.4× its normal reading; higher than 100% of its own history.
Reported lobbying spend: $30K in Q3 2022, $60K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Dec 2022
Ended
Dla Piper LLP (US)for Sab Biotherapeutics, Inc.
Federal contracts for biopharmaceuticals development.Pharmacy
Two or more unrelated kinds of records unusual within 30 days
17 Feb 2026confirmed
Confirmed across sources Institutional holdings and Short interest and volume
SAB Biotherapeutics(SABS): had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year, while it saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year. Two unrelated kinds of activity within 14 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
The 15 Jan 2026 report against the 24 reports before it.
this reportearliernormal: 122KSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
SAB Biotherapeutics had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.
This period
1.6M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
122K
Typical spread (median absolute deviation)
101K
How far from its usual level
+9.7
Same report last year
53K
History used
1,539 days
the 15 Jan 2026 report24 earlier reportsnormal: 122K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
SAB Biotherapeutics saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.
This period
20 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+5.3
Same quarter last year
4
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
SAB Biotherapeutics had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.
This period
1.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
265K
Typical spread (median absolute deviation)
232K
How far from its usual level
+4.9
Same report last year
118K
History used
1,554 days
the 30 Jan 2026 report24 earlier reportsnormal: 265K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
15 May 2026Institutional holdings change
saw 29 13F filers open a new position in the quarter ended 31 Mar 2026, 7.2× the same quarter last year.
Same quarter last year: 4; its normal quarter is 4.
See the evidence
This period
29 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+8.3
Same quarter last year
4
History used
1,643 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year, while it saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (3 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
SAB Biotherapeutics had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.
This period
1.6M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
122K
Typical spread (median absolute deviation)
101K
How far from its usual level
+9.7
Same report last year
53K
History used
1,539 days
the 15 Jan 2026 report24 earlier reportsnormal: 122K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
SAB Biotherapeutics saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.
This period
20 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+5.3
Same quarter last year
4
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
SAB Biotherapeutics had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.
This period
1.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
265K
Typical spread (median absolute deviation)
232K
How far from its usual level
+4.9
Same report last year
118K
History used
1,554 days
the 30 Jan 2026 report24 earlier reportsnormal: 265K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Feb 2026Institutional holdings change
saw 20 13F filers open a new position in the quarter ended 31 Dec 2025, 5.0× the same quarter last year.
Same quarter last year: 4; its normal quarter is 4.
See the evidence
This period
20 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
4
Typical spread (median absolute deviation)
1.5
How far from its usual level
+5.3
Same quarter last year
4
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 4
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 1.9M shares sold short in the 30 Jan 2026 report, 16× the same report last year.
Same report last year: 118K; its normal report is 265K.
See the evidence
This period
1.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
265K
Typical spread (median absolute deviation)
232K
How far from its usual level
+4.9
Same report last year
118K
History used
1,554 days
the 30 Jan 2026 report24 earlier reportsnormal: 265K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.6M shares sold short in the 15 Jan 2026 report, 29× the same report last year.
Same report last year: 53K; its normal report is 122K.
See the evidence
This period
1.6M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
122K
Typical spread (median absolute deviation)
101K
How far from its usual level
+9.7
Same report last year
53K
History used
1,539 days
the 15 Jan 2026 report24 earlier reportsnormal: 122K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.4M shares sold short in the 31 Dec 2025 report, 40× the same report last year.
Same report last year: 36K; its normal report is 117K.
See the evidence
This period
1.4M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
117K
Typical spread (median absolute deviation)
89K
How far from its usual level
+10.1
Same report last year
36K
History used
1,524 days
the 31 Dec 2025 report24 earlier reportsnormal: 117K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 901K shares sold short in the 15 Dec 2025 report, 16× the same report last year.
Same report last year: 56K; its normal report is 107K.
See the evidence
This period
901K (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
107K
Typical spread (median absolute deviation)
72K
How far from its usual level
+7.4
Same report last year
56K
History used
1,508 days
the 15 Dec 2025 report24 earlier reportsnormal: 107K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 702K shares sold short in the 28 Nov 2025 report, 7.1× the same report last year.
Same report last year: 99K; its normal report is 99K.
See the evidence
This period
702K (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
99K
Typical spread (median absolute deviation)
63K
How far from its usual level
+6.5
Same report last year
99K
History used
1,491 days
the 28 Nov 2025 report24 earlier reportsnormal: 99K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 677K shares sold short in the 14 Nov 2025 report, 17× the same report last year.
Same report last year: 40K; its normal report is 96K.
See the evidence
This period
677K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
96K
Typical spread (median absolute deviation)
57K
How far from its usual level
+6.8
Same report last year
40K
History used
1,477 days
the 14 Nov 2025 report24 earlier reportsnormal: 96K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 697K shares sold short in the 31 Oct 2025 report, 12× the same report last year.
Same report last year: 59K; its normal report is 82K.
See the evidence
This period
697K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
82K
Typical spread (median absolute deviation)
43K
How far from its usual level
+9.8
Same report last year
59K
History used
1,463 days
the 31 Oct 2025 report24 earlier reportsnormal: 82K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 693K shares sold short in the 15 Oct 2025 report, 8.7× the same report last year.
Same report last year: 80K; its normal report is 76K.
See the evidence
This period
693K (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
76K
Typical spread (median absolute deviation)
39K
How far from its usual level
+10.6
Same report last year
80K
History used
1,447 days
the 15 Oct 2025 report24 earlier reportsnormal: 76K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 502K shares sold short in the 15 Aug 2025 report, 19× the same report last year.
Same report last year: 26K; its normal report is 58K.
See the evidence
This period
502K (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
23K
How far from its usual level
+8.9
Same report last year
26K
History used
1,386 days
the 15 Aug 2025 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 746K shares sold short in the 31 Jul 2025 report, 26× the same report last year.
Same report last year: 29K; its normal report is 55K.
See the evidence
This period
746K (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
55K
Typical spread (median absolute deviation)
23K
How far from its usual level
+13.8
Same report last year
29K
History used
1,371 days
the 31 Jul 2025 report24 earlier reportsnormal: 55K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 665K shares sold short in the 15 May 2023 report, 2.6× the same report last year.
Same report last year: 259K; its normal report is 231K.
See the evidence
This period
665K (the 15 May 2023 report)
Normal report (median of 24 earlier)
231K
Typical spread (median absolute deviation)
33K
How far from its usual level
+8.7
Same report last year
259K
History used
563 days
the 15 May 2023 report24 earlier reportsnormal: 231K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 519K shares sold short in the 28 Apr 2023 report, 2.0× the same report last year.
Same report last year: 265K; its normal report is 231K.
See the evidence
This period
519K (the 28 Apr 2023 report)
Normal report (median of 24 earlier)
231K
Typical spread (median absolute deviation)
33K
How far from its usual level
+5.8
Same report last year
265K
History used
546 days
the 28 Apr 2023 report24 earlier reportsnormal: 231K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.
Not listed: 67 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001833214
Ticker
SABS
Domain
sab.bio
Hq location
FL|MIAMI BEACH|33140 (1 unverified)
Lobbying client
sab biotherapeutics
Name
Aurochs LLC, a South Dakota LLC, Big Cypress Acquisition Corp., Diversity Therapeutics, Inc., a Delaware Corporation, EX-21.1 and 6 more
Federal lobbying disclosures (LDA)6 records, 51 data points30 Sep 2014 to 31 Dec 2022
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)104 records7 Dec 2020 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)340 data points31 Dec 2019 to 2 Nov 2026
SEC Form 4 insider transactions13 records, 32 data points14 Jan 2021 to 8 Dec 2023
FINRA short interest (twice monthly)360 data points29 Oct 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2550 data points25 Oct 2021 to 20 Nov 2026